Trupanion provides medical insurance for cats and dogs in the United States, Canada, and select European markets. Its third-quarter 2026 results offer a useful test of whether the company can maintain its profitability turnaround while still expanding its subscriber base in an underpenetrated market. After a solid second quarter, attention centered on retention trends, the economics of acquiring new pets, and free cash flow generation. The ability to align pricing with double-digit veterinary inflation while reducing acquisition costs remains central to the longer-term margin outlook. These figures give a clearer picture of whether investments in brand awareness and product options are supporting durable growth.
Trupanion reported total revenue of $405.6 million for the third quarter of 2026, up 11% from a year earlier and ahead of the FactSet consensus near $402.5 million. Subscription revenue increased 14% to $287.9 million, while other business revenue rose 3% to $117.7 million. Net income came in at $9.3 million, or $0.21 per basic and diluted share, compared with $5.9 million, or $0.14 per share, in the prior-year period. Total monthly average revenue per pet climbed 8% to $88.95, and subscription pets reached 1,145,000 as of September 30. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Profitability metrics strengthened further. Subscription AOI reached a record $45.4 million, up 16% year over year, for a 15.8% margin. Total AOI rose 15% to $47 million. The average cost to acquire a pet declined to $279 from $290 a year earlier, pointing to better marketing efficiency. Management tightened its full-year 2026 outlook, now expecting total revenue between $1.59 billion and $1.597 billion and total AOI of $179 million to $182 million, which implies about 19% growth at the midpoint.
Trupanion came into the report with positive momentum after a strong beat and raise in the second quarter. The third-quarter results reinforced that trend: revenue exceeded consensus, profitability extended its streak, free cash flow hit a record, and guidance was raised. These elements are generally viewed positively by investors focused on the path to sustained profitability. At the same time, sentiment remains sensitive to the value proposition metric, which slipped modestly to 69.7% from 70.1% a year ago. Overall, the combination of record AOI, lower pet acquisition costs, and raised guidance suggests investors saw the report as confirmation that the growth and margin trajectory remains on track.
Looking ahead, the focus will be on whether Trupanion can sustain its improving unit economics. The drop in average pet acquisition cost from $290 to $279 signals that marketing and brand spending are becoming more efficient, which should support both faster pet growth and stronger margins. Retention will stay important. Average monthly retention rose for a seventh straight quarter to 98.38%, underpinning the recurring-revenue model. Maintaining that level while expanding new deductible and co-insurance options will test product flexibility. Veterinary inflation remains a key item to monitor, as the model prices coverage to track rising costs. The recent partnership with Simon Cowell adds a brand-awareness catalyst. Capital allocation also deserves attention: the company repurchased roughly 830,000 shares for about $25 million and ended the quarter with $396.8 million in cash and short-term investments against $104.5 million in debt.
In my day-to-day research I frequently rely on Tickeron’s AI Screener to quickly surface comparable companies and test ideas against the same fundamentals we reviewed here. It helps me stay efficient when scanning the broader insurance space without losing sight of the specific metrics that matter for names like Trupanion.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TRUP moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 06, 2026. You may want to consider a long position or call options on TRUP as a result. In 73 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for TRUP just turned positive on October 05, 2026. Looking at past instances where TRUP's MACD turned positive, the stock continued to rise in 41 of 52 cases over the following month. The odds of a continued upward trend are 79%.
The 10-day moving average for TRUP crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
The 50-day moving average for TRUP moved above the 200-day moving average on October 15, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +9.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRUP advanced for three days, in 208 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 119 of 152 cases where TRUP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 21 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
TRUP broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. TRUP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.606) is normal, around the industry mean (-2.448). TRUP has a moderately high P/E Ratio (63.538) as compared to the industry average of (9.472). TRUP's Projected Growth (PEG Ratio) (24.710) is slightly higher than the industry average of (3.303). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (0.736) is also within normal values, averaging (1.594).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRUP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 51, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company that engages in providing pet health insurance services
Industry PropertyCasualtyInsurance